Rezolute Announces Positive Phase 3 Trial Results for Ersodetug in Tumor Hyperinsulinism

Rezolute, Inc. has reported positive preliminary results from its open-label Phase 3 upLIFT study of ersodetug, a treatment for tumor hyperinsulinism. The trial successfully met its primary efficacy endpoint, indicating promising outcomes for individuals with this rare metabolic condition. Full topline data are expected by mid-December 2026, which will provide more comprehensive insights into the drug's performance.